OncoMatch/Clinical Trials/NCT05615623
Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG
Is NCT05615623 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Exablate and Doxorubicin for brain tumor.
Treatment: Exablate · Doxorubicin — The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type 2.0/2.1 in combination with Doxorubicin therapy for the treatment of DIPG in pediatric patients
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Prior therapy
Must have received: radiation therapy
At least 4-week and not greater than 12 weeks from completion of radiation therapy
Cannot have received: anthracycline (doxorubicin, daunorubicin, idarubicin)
Previous treatment with complete cumulative doses of Doxorubicin, daunorubicin, idarubicin, and/or other anthracyclines and anthracenediones
Cannot have received: chemotherapy
Previous participation in other chemotherapy, molecularly targeted therapy or immunotherapy treatment-related phase 1 or 2 trials
Cannot have received: molecularly targeted therapy
Previous participation in other chemotherapy, molecularly targeted therapy or immunotherapy treatment-related phase 1 or 2 trials
Cannot have received: immunotherapy
Previous participation in other chemotherapy, molecularly targeted therapy or immunotherapy treatment-related phase 1 or 2 trials
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify